Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Sweeney

Showing results (1-10 of 263) with videos related to

Pageof 27
Sort By:
Hematology/Oncology Clinics of North America|November 6, 2013
Preface. Prostate cancerChristopher J Sweeney
American Journal of Clinical Oncology|August 7, 2003
Why cyclooxygenase-2 inhibition plus chemotherapy?Christopher J Sweeney
European Urology|July 16, 2018
Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?Christopher J Sweeney
Clinical Advances in Hematology & Oncology : H&O|November 23, 2006
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancerChristopher J Sweeney
JAMA Oncology|September 18, 2015
The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation TherapyChristopher J Sweeney
European Urology Focus|March 23, 2019
Time for an Integrated Global Strategy to Decrease Deaths from Prostate CancerChristopher J Sweeney
Future Oncology (London, England)|March 12, 2015
Insights into E3805: the CHAARTED trialChristopher J Sweeney, Dominic Chamberlain
Surgical Pathology Clinics|November 28, 2015
Diagnosis and Treatment of Testicular Cancer: A Clinician's PerspectiveBrandon Bernard, Christopher J Sweeney
European Urology|May 18, 2016
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate CancerEdoardo Francini, Christopher J Sweeney
Current Urology Reports|February 14, 2015
Management of metastatic hormone-sensitive prostate cancerBrandon Bernard, Christopher J Sweeney
Pageof 27

Showing results (1-10 of 263) with videos related to

Sort By:
Pageof 27
Hematology/Oncology Clinics of North America|November 6, 2013
Preface. Prostate cancerChristopher J Sweeney
American Journal of Clinical Oncology|August 7, 2003
Why cyclooxygenase-2 inhibition plus chemotherapy?Christopher J Sweeney
European Urology|July 16, 2018
Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?Christopher J Sweeney
Clinical Advances in Hematology & Oncology : H&O|November 23, 2006
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancerChristopher J Sweeney
JAMA Oncology|September 18, 2015
The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation TherapyChristopher J Sweeney
European Urology Focus|March 23, 2019
Time for an Integrated Global Strategy to Decrease Deaths from Prostate CancerChristopher J Sweeney
Future Oncology (London, England)|March 12, 2015
Insights into E3805: the CHAARTED trialChristopher J Sweeney, Dominic Chamberlain
Surgical Pathology Clinics|November 28, 2015
Diagnosis and Treatment of Testicular Cancer: A Clinician's PerspectiveBrandon Bernard, Christopher J Sweeney
European Urology|May 18, 2016
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate CancerEdoardo Francini, Christopher J Sweeney
Current Urology Reports|February 14, 2015
Management of metastatic hormone-sensitive prostate cancerBrandon Bernard, Christopher J Sweeney
Pageof 27